Cutaneous side-effects of kinase inhibitors and blocking antibodies

Demetri, 2002, Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors, N Engl J Med, 347, 472, 10.1056/NEJMoa020461 Perez-Soler, 2003, Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?, Oncology (Huntingt), 17, 23 Robert, 2003, Tyrosine kinase inhibition and grey hair, Lancet, 361, 1056, 10.1016/S0140-6736(03)12805-X Herbst, 2004, Gefitinib: a novel targeted approach to treating cancer, Nat Rev Cancer, 4, 956, 10.1038/nrc1506 Mendelsohn, 2003, Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer, J Clin Oncol, 21, 2787, 10.1200/JCO.2003.01.504 Spigel, 2005, Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC): update of a phase II multicenter trial, Proc Am Soc Clin Oncol, 10.1200/jco.2005.23.16_suppl.4540 Pautier, 2004, Preliminary results of a phase II study to evaluate gefitinib (ZD1839) combined with paclitaxel (P) and carboplatin (C) as second-line therapy in patients (pts) with ovarian carcinoma (OC), Proc Am Soc Clin Oncol, 22 Cunningham, 2004, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer, N Engl J Med, 351, 337, 10.1056/NEJMoa033025 Busam, 2001, Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225, Br J Dermatol, 144, 1169, 10.1046/j.1365-2133.2001.04226.x Jacot, 2004, Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours, Br J Dermatol, 151, 238, 10.1111/j.1365-2133.2004.06026.x Van Doorn, 2002, Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor, Br J Dermatol, 147, 598, 10.1046/j.1365-2133.2002.04864.x Albanell, 2002, Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition, J Clin Oncol, 20, 110, 10.1200/JCO.20.1.110 Mak, 2003, Epidermal growth factor as a biologic switch in hair growth cycle, J Biol Chem, 278, 26120, 10.1074/jbc.M212082200 Murillas, 1995, Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure, EMBO J, 14, 5216, 10.1002/j.1460-2075.1995.tb00206.x Mascia, 2003, Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation, Am J Pathol, 163, 303, 10.1016/S0002-9440(10)63654-1 Robert, 1999, Inflammatory skin diseases, T cells, and immune surveillance, N Engl J Med, 341, 1817, 10.1056/NEJM199912093412407 Perez-Soler, 2004, Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer, J Clin Oncol, 22, 3238, 10.1200/JCO.2004.11.057 Cohen, 2003, Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck, J Clin Oncol, 21, 1980, 10.1200/JCO.2003.10.051 Mohamed, 2005, Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer, Ann Oncol, 16, 780, 10.1093/annonc/mdi157 Chrysogelos, 1993, Chromatin structure of the EGFR gene suggests a role for intron 1 sequences in its regulation in breast cancer cells, Nucleic Acids Res, 21, 5736, 10.1093/nar/21.24.5736 Buerger, 2000, Length and loss of heterozygosity of an intron 1 polymorphic sequence of EGFR is related to cytogenetic alterations and epithelial growth factor receptor expression, Cancer Res, 60, 854 Gebhardt, 1999, Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1, J Biol Chem, 274, 13176, 10.1074/jbc.274.19.13176 Amador, 2004, An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors, Cancer Res, 64, 9139, 10.1158/0008-5472.CAN-04-1036 Shah, 2005, Practical management of patients with non-small-cell lung cancer treated with gefitinib, J Clin Oncol, 23, 165, 10.1200/JCO.2005.04.057 Koistinaho, 2004, Tetracycline derivatives as anti-inflammatory agents and potential agents in stroke treatment, Ernst Schering Res Found Workshop, 101 Krakauer, 2003, Doxycycline is anti-inflammatory and inhibits staphylococcal exotoxin-induced cytokines and chemokines, Antimicrob Agents Chemother, 47, 3630, 10.1128/AAC.47.11.3630-3633.2003 Amsden, 2005, Anti-inflammatory effects of macrolides—an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?, J Antimicrob Chemother, 55, 10, 10.1093/jac/dkh519 Dueland, 2003, Epidermal growth factor receptor inhibition induces trichomegaly, Acta Oncol, 42, 345, 10.1080/02841860310006038 Threadgill, 1995, Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype, Science, 269, 230, 10.1126/science.7618084 Sibilia, 1995, Strain-dependent epithelial defects in mice lacking the EGF receptor, Science, 269, 234, 10.1126/science.7618085 McLaren, 1971, The microscopic appearance of waved-2 mouse hairs, Genet Res, 17, 257, 10.1017/S0016672300012271 Almagro, 2003, Eyelash length in HIV infected patients, AIDS, 17, 1695, 10.1097/00002030-200307250-00015 Valiathan, 2004, Expression of human immunodeficiency virus type 1 gag modulates ligand-induced downregulation of EGF receptor, J Virol, 78, 12386, 10.1128/JVI.78.22.12386-12394.2004 Bonaccorsi, 2004, EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR), Int J Cancer, 112, 78, 10.1002/ijc.20362 Huang, 2004, Proteomic identification of 14-3-3 sigma as a common component of the androgen receptor and the epidermal growth factor receptor signaling pathways of the human prostate epithelial cell line M12, Oncogene, 23, 6881, 10.1038/sj.onc.1207788 Mellinghoff, 2004, HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability, Cancer Cell, 6, 517, 10.1016/j.ccr.2004.09.031 Kalli, 2004, Estrogen receptor-positive human epithelial ovarian carcinoma cells respond to the antitumor drug suramin with increased proliferation: possible insight into ER and epidermal growth factor signaling interactions in ovarian cancer, Gynecol Oncol, 94, 705, 10.1016/j.ygyno.2004.05.059 Boucher, 2002, Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody, J Am Acad Dermatol, 47, 632, 10.1067/mjd.2002.124621 Baran, 1986, Etretinate and the nails (study of 130 cases) possible mechanisms of some side-effects, Clin Exp Dermatol, 11, 148, 10.1111/j.1365-2230.1986.tb00439.x Bouscarat, 1998, Paronychia and pyogenic granuloma of the great toes in patients treated with indinavir, N Engl J Med, 338, 1776, 10.1056/NEJM199806113382417 Lee, 1993, Phase I evaluation of all-trans-retinoic acid in adults with solid tumors, J Clin Oncol, 11, 959, 10.1200/JCO.1993.11.5.959 Ward, 2002, Cutaneous manifestations of antiretroviral therapy, J Am Acad Dermatol, 46, 284, 10.1067/mjd.2002.119105 Sah, 2002, Retinoids suppress epidermal growth factor-associated cell proliferation by inhibiting epidermal growth factor receptor-dependent ERK1/2 activation, J Biol Chem, 277, 9728, 10.1074/jbc.M110897200 Song, 2001, Abrogation of transforming growth factor-alpha/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines, Cancer Res, 61, 5919 Hong, 1998, Signaling by tyrosine kinases negatively regulates the interaction between transcription factors and SMRT (silencing mediator of retinoic acid and thyroid hormone receptor) corepressor, Mol Endocrinol, 12, 1161, 10.1210/mend.12.8.0160 Druker, 2001, Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia, N Engl J Med, 344, 1031, 10.1056/NEJM200104053441401 Guilhot, 2004, Indications for imatinib mesylate therapy and clinical management, Oncologist, 9, 271, 10.1634/theoncologist.9-3-271 Ahmad, 2004, Kinase inhibition with BAY 43-9006 in renal cell carcinoma, Clin Cancer Res, 10, S6388, 10.1158/1078-0432.CCR-040028 Wilhelm, 2004, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis, Cancer Res, 64, 7099, 10.1158/0008-5472.CAN-04-1443 Mendel, 2003, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship, Clin Cancer Res, 9, 327 O'Farrell, 2003, SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo, Blood, 101, 3597, 10.1182/blood-2002-07-2307 Motzer, 2004, SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial, Proc Am Soc Clin Oncol, 14 Nagore, 2000, Antineoplastic therapy-induced palmar plantar erythrodysesthesia (‘hand-foot’) syndrome. Incidence, recognition and management, Am J Clin Dermatol, 1, 225, 10.2165/00128071-200001040-00004 Young, 1988, Splinter haemorrhages: facts and fiction, J R Coll Physicians Lond, 22, 240 Platts, 1958, Splinter haemorrhages, Br Med J, 34, 143, 10.1136/bmj.2.5089.143 Mujic, 1995, Prevalence and clinical significance of subungual splinter haemorrhages in patients with the antiphospholipid syndrome, Clin Exp Rheumatol, 13, 327 Quenneville, 1981, Subungueal-splinter hemorrhage an early sign of thromboangiitis obliterans, Angiology, 32, 424, 10.1177/000331978103200609 Monk, 1980, The prevalence of splinter haemorrhages, Br J Dermatol, 103, 183, 10.1111/j.1365-2133.1980.tb06588.x Heath, 1978, Nail haemorrhages, Br Heart J, 40, 1300, 10.1136/hrt.40.11.1300 Martin, 1959, A histological study of the nail region in normal human subjects and in those showing splinter haemorrhages of the nail, J Anat, 93, 323 C Robert, Faivre, S, Raymond, E, et al. VEGF-receptor inhibition and subungual splinter hemorrhages (in press). Moss, 2003, Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans, J Pharmacol Exp Ther, 307, 476, 10.1124/jpet.103.052530 Botchkareva, 2001, SCF/c-kit signaling is required for cyclic regeneration of the hair pigmentation unit, FASEB J, 15, 645, 10.1096/fj.00-0368com Luo, 1995, Coordinated mRNA expression of c-Kit with tyrosinase and TRP-1 in melanin pigmentation of normal and malignant human melanocytes and transient activation of tyrosinase by Kit/SCF-R, Melanoma Res, 5, 303, 10.1097/00008390-199510000-00002 Sharov, 2003, Fas and c-kit are involved in the control of hair follicle melanocyte apoptosis and migration in chemotherapy-induced hair loss, J Invest Dermatol, 120, 27, 10.1046/j.1523-1747.2003.12022.x Hemesath, 1998, MAP kinase links the transcription factor microphthalmia to c-Kit signalling in melanocytes, Nature, 391, 298, 10.1038/34681 Etienne, 2002, Imatinib mesylate and gray hair, N Engl J Med, 347, 446, 10.1056/NEJM200208083470614 Wu, 2000, c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi, Genes Dev, 14, 301, 10.1101/gad.14.3.301 Valeyrie, 2003, Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients, J Am Acad Dermatol, 48, 201, 10.1067/mjd.2003.44 Tsao, 2003, Imatinib mesylate causes hypopigmentation in the skin, Cancer, 98, 2483, 10.1002/cncr.11812 Hensley, 2003, Imatinib treatment: Specific issues related to safety, fertility, and pregnancy, Semin Hematol, 40, 21, 10.1053/shem.2003.50038 Goldsby, 2002, Unexpected pleural effusions in 3 pediatric patients treated with STI-571, J Pediatr Hematol Oncol, 24, 694, 10.1097/00043426-200211000-00020 Ebnoether, 2002, Cerebral oedema as a possible complication of treatment with imatinib, Lancet, 359, 1751, 10.1016/S0140-6736(02)08616-6 Khachigian, 2000, Mechanisms of angiotensin II-induced platelet-derived growth factor gene expression, Mol Cell Biochem, 212, 183, 10.1023/A:1007153025897 Heuchel, 1999, Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3' kinase signaling, Proc Natl Acad Sci USA, 96, 11410, 10.1073/pnas.96.20.11410 Fraunfelder, 2003, Ocular side-effects associated with imatinib mesylate (Gleevec), J Ocul Pharmacol Ther, 19, 371, 10.1089/108076803322279426